Plant Health Care - Trading Statement
06/02/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230206:nRSF9312Oa&default-theme=true
RNS Number : 9312O Plant Health Care PLC 06 February 2023
6 February 2023
Plant Health Care plc
("Plant Health Care" or the "Company")
FY2022 Trading Statement
On track to achieve revenue of $30 million by 2025
Plant Health Care(®) (AIM.PHC.L), a leading provider of peptides for plant
protection to global agriculture markets, announces its trading update for the
12-month period to 31 December 2022.
Financial highlights:
· Revenue up 40% to $11.8m (2021: $8.4m)
o Sales in North America up 74%, driven by strong Harpin ab demand
o Sales in South America up 104%, driven by Saori(®) launch in soybeans and
Harpin ab sales in sugar cane
· Saori sales of $0.8m in first year since launch
· Harpin αβ sales increased by 36% to $8.2m (2021: 6.0m)
· Third party product revenue up 17% to $2.8m (2021: 2.4m)
· Gross margin improved 200 basis points to 61% (2021: 59%)
· LBITDA improved 24% to $3.5m (2021 $4.6m)
Cash:
· Cash and cash equivalents as of 31 December 2022 of $5.7m
· Substantial improvement in working capital which decreased 21% to
$3.1m (2021: $3.9m)
· Cash used in operations decreased 16% to $2.7m (2021: $3.2m)
· Company is on track to deliver cash breakeven, profitability and
internally funded growth within existing financial resources
Operational highlights:
Commercial - Harpin αβ
· In April, appointed Ager Agro SAS as a distributor of
Harpin αβ product, ProAct(®), in Argentina and Uruguay with first sales
in Argentina in Q4 2022.
· Successfully registered Harpin αβ for use as a fertilizer with
biostimulant properties in France, the largest agricultural producer in the
European Union. The EU mutual recognition process will help expand the use
of Harpin αβ to other European countries.
· Low-cost production agreement for Harpin αβ signed with a leading
Europe-based
biomanufacturing company; secures capacity to accommodate long-term growth in
demand and ensures gross margin.
New Technology - PREtec (Vaccines for Plants(TM)) platform
· Company plans one major new product launch every year from the PREtec
platform.
· Launch in 2021 of the first PREtec product Saori(®) in Brazil, the
world's largest soybean market, has been well received. Revenue of $0.8m in
FY2022; Signed long-term commercial agreement with Nutrien for distribution of
Saori in Brazil.
· Submitted applications to the regulatory agencies in Brazil for
approval to commercialize new PREtec products, PHC279 and PHC949, for use on
major crops.
· US registration for PHC279 pending following delays caused by backlog
at the US Environmental Protection Agency (EPA). EPA approval expected by end
of Q1 2023.
· In August, announced a trials agreement with Agrii UK under which Agrii
will evaluate PREtec technology for use in the UK.
· Signed an agreement for EDAF Unipessoal LDA to become the exclusive
distributor in Portugal for a proprietary PREtec-containing fertilizer,
PREzym™, for use in fruit, vegetables, and cereals crop production.
Post-period highlights:
· In January 2023, signed an agreement for the exclusive distribution of
Harpin αβ with Novozymes South Asia Pvt. for use in sugar cane production
in India.
Outlook:
· Company has seen continued growth into 2023 as it builds key global
distributor relationships for Harpin ab market expansion based on new
registration approvals.
· Saori is expected to be a significant driver of growth, building on
its successful launch in Brazil.
Jeff Tweedy, CEO of Plant Health Care, said: "2022 was excellent despite the
challenging macroeconomic conditions. Our success was driven by the growing
demand for Harpin αβ in North and South America and the successful
commercialisation of Saori in Brazil following its launch in 2021.
"We expect Saori to be a significant driver of growth especially in Brazil.
It has the potential to deliver disease control and yield increase worth
approximately US$75 per hectare for Brazilian soybean growers, giving them
an ROI of six times or more, while reducing the use of potentially less safe
agrochemicals. Brazilian soybean farmers spent US$2.85bn on disease control
in the 2020/21 season. Early in 2022, we signed a new long-term commercial
agreement with Nutrien for distribution of Saori in Brazil.
"Plant Health Care has continued to expand into new markets around the world
and has grown our relationships with major distribution partners. This year,
we started selling ProAct in Argentina. After the year-end, we announced a
deal for distribution of Harpin αβ in India.
"We plan to launch one major PREtec product each year building on the success
of Saori. Applications have been submitted to the regulatory agencies in
Brazil for approval to commercialize new PREtec products PHC279 and PHC949 for
use on major crops.
"Plant Health Care is on track to achieve revenue of $30 million by 2025
through the launch of new peptides, and growth through current and future
distributor relationships and deliver cash breakeven within our existing cash
reserves."
For further information, please contact:
Plant Health Care plc
Jeff Tweedy, CEO
Tel: +1 919 926 1600
Cenkos Securities plc - Nomad & Broker
Neil McDonald / Pete Lynch
Tel: +44 (0) 131 220 9771
SEC Newgate (Financial Communications) Tel: +44 (0)7540 106 366
Robin Tozer / George Esmond / Harry Handyside Email: phc@secnewgate.co.uk (mailto:phc@secnewgate.co.uk)
About Plant Health Care
Plant Health Care offers products to improve the health, vigour and yield of
major field crops such as corn, soybeans, potatoes, and rice, as well as
specialty crops such as fruits and vegetables. We operate globally through
subsidiaries, distributors and supply agreements with major industry partners.
Our innovative, patent-protected biological products help growers to protect
their crops from stress and diseases, and to produce higher quality fruit and
vegetables, with a favourable environmental profile.
Find out more at www.planthealthcare.com (http://www.planthealthcare.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTFLFIDFAIVIIV